You are here: Industry Insights > Lemtrada

News List

Updated restrictions announced for multiple sclerosis treatment europeanpharmaceuticalreview
March 11, 2020
A revised indication, additional contraindications and strengthened monitoring requirements has been recommended for Lemtrada (alemtuzumab) following a review.
Use of Genzyme's MS drug Lemtrada restricted under ongoing EMA safety review pharmafile
April 17, 2019
The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports emerged of treatment-related safety issues arising from heart
EMA recommends temporarily restricting Lemtrada use in MS pharmatimes
April 16, 2019
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has started a ……
EMA restricts use of multiple sclerosis medicine, Lemtrada europeanpharmaceuticalreview
April 16, 2019
EMA restricts use of multiple sclerosis medicine, Lemtrada.
FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug drugs
December 06, 2018
A new warning has been added to the multiple sclerosis drug Lemtrada (alemtuzumab) after rare reports of patients suffering strokes and tears in the lining of the arteries in the head and neck, the U.S. Food and Drug Administration said.....
FDA warns risks with multiple sclerosis drug Lemtrada (alemtuzumab) fda
November 30, 2018
FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)